Laboratory of Dermatopathology ADX, LLC Notifies Patients of Data Security Incident

WOODBURY, N.Y., July 19, 2019 /PRNewswire/ — Laboratory of Dermatopathology ADX, LLC (“LDA”), has been informed by Retrieval Masters Creditors Bureau d/b/a American Medical Collection Agency (“AMCA”) of a data security incident involving the AMCA payment website.  AMCA is an independent collection agency that LDA and many other entities used for debt collection.  The incident is limited to AMCA’s systems.  The security of LDA’s systems was not affected by this incident.

According to AMCA, on March 21, 2019, AMCA became aware of facts indicating there had been a data security incident. After conducting an investigation, in May of 2019, AMCA notified LDA about the incident and informed LDA that an AMCA database containing information for some LDA patients had been affected.  However, at the time of AMCA’s initial notification, AMCA did not provide LDA with enough information for LDA to identify potentially affected patients or confirm the nature of patient information potentially involved in the incident, and LDA’s investigation is on-going. Based on the information provided by AMCA, the following information belonging to LDA patients may have been affected by the incident: patient names, addresses, phone numbers, dates of birth, dates of service, balance information, credit card or banking information and treatment provider information.  AMCA has advised LDA that its patient’s social security numbers were not involved in the incident.  LDA does not provide AMCA healthcare records such as laboratory results and clinical history. 

In response to the breach, AMCA sent notification letters to approximately 240 LDA patients informing them that their names, addresses, phone numbers, dates of birth, dates of service, balance information, credit card or banking information and treatment provider information may have been impacted.  In addition, based on the investigation and the information provided by AMCA, LDA estimates that approximately another 4,000 patients may have had their names, addresses, phone numbers, dates of birth, dates of service, balance information and treatment provider information impacted by this incident.  For these patients, credit card and banking information is not affected. The impact of this incident is limited to laboratory services provided to patients in the United States whose accounts were referred for debt collection.

Individuals with questions about this incident or questions about precautionary steps they can take may call 833-300-6928 for additional information.

Laboratory of Dermatopathology ADX, LLC takes the security of its patients’ information very seriously, including the security of data handled by vendors.  As a result of the investigation, LDA is no longer using AMCA for collection efforts.

The privacy and protection of patient information is a top priority.  LDA greatly appreciates the patience and loyalty of its patients as it works to respond to this incident.

View original content:http://www.prnewswire.com/news-releases/laboratory-of-dermatopathology-adx-llc-notifies-patients-of-data-security-incident-300888266.html

SOURCE Laboratory of Dermatopathology ADX, LLC

Staff

Recent Posts

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

1 hour ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

1 hour ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

1 hour ago

Calm Nature CBD Gummies Ingredients: 2026 Consumer Analysis Examines Full Spectrum CBD Claims, Testing Standards, and Formulation Transparency

Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…

1 hour ago